From CNBC: 2024-08-30 15:50:23

The FDA authorized Novavax’s updated protein-based Covid vaccine for emergency use in people ages 12 and up, targeting the omicron subvariant JN.1. Novavax’s shot is expected to compete with Pfizer and Moderna’s jabs this fall and winter. Shares of Novavax rose more than 8% following the announcement.

Novavax’s vaccine targets the highly contagious omicron subvariant JN.1, which currently accounts for 0.2% of cases nationwide. The shot provides protection against several descendants of JN.1, currently dominant in the U.S. Novavax expects its vaccine to be broadly available in thousands of locations across the country, including pharmacies and grocers.

Novavax’s CEO stated that the updated vaccine targets JN.1, the parent strain of circulating variants, with proven cross-reactivity against related viruses. The FDA’s authorization comes in the wake of approving new mRNA shots from Pfizer and Moderna, which target another offshoot of JN.1 known as KP.2.

Public health officials view Novavax’s vaccine as a valuable alternative to mRNA shots. Only around 22.5% of US adults received the latest round of shots last fall, according to CDC data. Novavax’s protein-based technology has been used in routine vaccinations against hepatitis B and shingles, offering a tried and true approach to Covid protection.



Read more at CNBC: FDA authorizes Novavax Covid vaccine targeting JN.1